logo-loader
viewANGLE PLC

ANGLE CEO eyes research market sales following Barts endorsement

Andrew Newland, founder and chief executive of ANGLE plc (LON:AGL), says the medical diagnostic company is on course to deliver sales of its Parsortix system to the research market later this calendar year.

Newland was speaking to Proactive following publication of the first peer-reviewed paper of Parsortix in a journal by Barts Cancer Institute, one of ANGLE’s key opinion leaders.

They assessed the device’s ability to pick up signs of prostate cancer from blood samples and found Parsortix to be superior in many ways to the current gold standard - antibody-based detection.

Quick facts: ANGLE PLC

Price: 60.91 GBX

AIM:AGL
Market: AIM
Market Cap: £105.22 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Angle’s Newland reflects on excellent year as cancer patient trials advance

Angle Plc (LON:AGL, OTCMKTS:ANPCY) is poised to revolutionise cancer treatment with its Parsortix system, here we catch up with chief executive Andrew Newland. As Newland explains Parsortix can capture cancer cells from blood, which is very significant for the emerging field of...

on 07/28/2016

2 min read